Research and advances on resistance mechanism of Acinetobacter baumannii
YANG Bin-yi1, YAO Dong-mei2
1. Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China; 2. The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
Abstract：Acinetobacter baumannii (A. baumannii) belongs to Gram-negative bacilli, and its related resistance mechanism is very complicated, especially in extensively drug-resistant Acinetobacter baumannii (XDRAB) and pan drug-resistant Acinetobacter baumannii (PDRAB).A. baumannii is resistant to a variety of antibiotics due to the mechanisms of drug inactivation enzymes and efflux pumps; and hence, clinical treatment has become very difficult, with a high mortality rate in the patients. This study is mainly to review the research progress of resistance mechanism ofA. baumannii in recent years and summarize the currently widely used treatment methods.
杨彬艺, 姚冬梅. 鲍曼不动杆菌耐药机制的研究及进展[J]. 实用预防医学, 2019, 26(6): 766-769.
YANG Bin-yi, YAO Dong-mei. Research and advances on resistance mechanism of Acinetobacter baumannii. , 2019, 26(6): 766-769.
[1] 赵智慧, 王晓莉, 马志强. 使用替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌肺炎的临床研究[J].中国药房,2017,28(2):201-204. [2] Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence[J]. Nat Rev Microbiol, 2018,16(2):91-102. [3] 黄洪琳, 易斌. 长期住院老年患者下呼吸道感染病原菌分布及耐药性分析[J].实用预防医学,2017,24(4):454-457. [4] Wood CR, Mack LE, Actis LA. An update on the Acinetobacter baumannii regulatory circuitry[J]. Trends Microbiol, 2018,26(7):560-562. [5] 胡付品, 朱德妹, 汪复, 等. 2014年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2015,15(5):401-410. [6] 张静, 赵水娣, 张之烽. 南京市部分地区医院感染鲍曼不动杆菌的耐药基因和分子流行病学研究[J].国际检验医学杂志,2017,38(1):74-76,79. [7] Cecchini T, Yoon EJ, Charretier Y, et al. Deciphering multifactorial resistance phenotypes in Acinetobacter baumannii by genomics and targeted label-free proteomics[J]. Mol Cell Proteomics, 2017,17(3):442-456. [8] Thomson GK, Ayaz M, Lutes K, et al. An improved extended-spectrum-β-lactamase detection test utilizing aztreonam plus clavulanate[J].J Clin Microbiol,2018,56(1):1-6. [9] Tohamy ST, Aboshanab KM, El-Mahallawy HA, et al. Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations[J]. Infect Drug Resist, 2018,11:791-803. [10] 涂盛, 邵安文, 朱曼华, 等. 鲍曼不动杆菌的临床分布、耐药情况及其感染危险因素分析[J].中国微生态学杂志,2016,28(12):1416-1419,1428. [11] Domingues S, Rosário N, Ben CH, et al. ISAba1 and Tn6168 acquisition by natural transformation leads to third-generation cephalosporins resistance in Acinetobacter baumannii[J]. Infect Genet Evol, 2018,63:13-16. [12] 方乐, 胡江, 陈敬银, 等. 2013－2015年887株鲍曼不动杆菌的临床感染分布及耐药分析[J].现代预防医学,2016,43(12):2275-2279. [13] Han L, Lei J, Xu J, et al. blaOXA-23-like and blaTEM rather than blaOXA-51-like contributed to a high level of carbapenem resistance in Acinetobacter baumannii strains from a teaching hospital in Xi'an, China[J]. Medicine (Baltimore), 2017,96(48):e8965. [14] Royer S, de Campos PA, Araújo BF, et al. Molecular characterization and clonal dynamics of nosocomial blaOXA-23 producing XDR Acinetobacter baumannii[J]. PLoS One, 2018,13(6):e0198643. [15] Pagdepanichkit S, Tribuddharat C, Chuanchuen R. Distribution and expression of the Ade multidrug efflux systems in Acinetobacter baumannii clinical isolates[J]. Can J Microbiol, 2016,62(9):794-801. [16] 王珏鑫, 余广超, 温旺荣. 鲍曼不动杆菌对碳青霉烯类抗菌药物耐药机制研究进展[J].中国抗生素杂志,2016,41(11):824-828. [17] Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii[J]. J Antimicrob Chemother, 2007,59(6):1210-1215. [18] 王鹏, 奚敏, 余永胜, 等. 鲍曼不动杆菌中外排泵介导耐药机制的研究进展[J].微生物与感染,2016,11(5):297-301. [19] Okada U, Yamashita E, Neuberger A, et al. Crystal structure of tripartite-type ABC transporter MacB from Acinetobacter baumannii[J]. Nat Commun, 2017,8(1):1336. [20] Lin MF, Lin YY, Lan CY. The role of the two-component system BaeSR in disposing chemicals through regulating transporter systems in Acinetobacter baumannii[J]. PLoS One, 2015,10(7):e0132843. [21] Yoon EJ, Courvalin P, Grillot-Courvalin C. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations[J]. Antimicrob Agents Chemother, 2013,57(7):2989-2995. [22] Lin F, Xu Y, Chang Y, et al. Molecular characterization of reduced susceptibility to biocides in clinical isolates of Acinetobacter baumannii[J]. Front Microbiol, 2017,8:1836. [23] 豆清娅, 邹明祥, 李军, 等. AdeABC外排泵系统与鲍曼不动杆菌对碳青霉烯类药物耐药的关系[J].中南大学学报(医学版),2017,42(4):426-433. [24] Sun JR, Chiang YS, Shang HS, et al. Phenotype microarray analysis of the AdeRS two-component system in Acinetobacter baumannii[J]. Eur J Clin Microbiol Infect Dis, 2017,36(12):2343-2353. [25] Rumbo C, Gato E, López M, et al. Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii[J].Antimicrob Agents Chemother,2013,57(11):5247-5257. [26] Pournaras S, Koumaki V, Gennimata V, et al. In vitro activity of tigecycline against Acinetobacter baumannii: global epidemiology and resistance mechanisms[J]. Adv Exp Med Biol, 2016,897:1-14. [27] Pérez-Varela M, Corral J, Aranda J, et al. Functional characterization of AbaQ, a novel efflux pump mediating quinolone resistance in Acinetobacter baumannii[J]. Antimicrob Agents Chemother, 2018,62(9):e00906-00918. [28] Sharma A, Sharma R, Bhattacharyya T, et al. Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF[J]. J Antimicrob Chemother, 2017,72(1):68-74. [29] Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp.[J]. Antimicrob Agents Chemother, 2011,55(3):947-953. [30] Srinivasan VB, Vaidyanathan V, Rajamohan G. AbuO, a TolC-like outer membrane protein of Acinetobacter baumannii, is involved in antimicrobial and oxidative stress resistance[J]. Antimicrob Agents Chemother, 2015,59(2):1236-1245. [31] 袁星, 沈继录, 徐元宏. 鲍曼不动杆菌对喹诺酮类药物耐药机制的研究进展[J].现代检验医学杂志,2010,25(3):157-159. [32] 杨茁, 刘凌华, 张利侠, 等. 耐氟喹诺酮类鲍曼不动杆菌Parc的变异研究[J].现代检验医学杂志,2015,30(1):25-26,31. [33] 王蕾, 郭存九. 鲍曼不动杆菌碳青霉烯酶及其耐药机制的研究进展[J].中国药物与临床,2016,16(6):839-843. [34] Papp-Wallace KM, Nguyen NQ, Jacobs MR, et al. Strategic approaches to overcome resistance against Gram negative pathogens using β-lactamase inhibitors and β-lactam enhancers: activity of three novel diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234[J].J Med Chem,2018,61(9):4067-4086. [35] 温海初, 牛雨佳, 陈丽华. 鲍曼不动杆菌耐药性相关基因及其调控机制研究进展[J].临床检验杂志,2016,34(2):137-139. [36] Park YJ, Hong DJ, Yoon EJ, et al. Differences in colistin-resistant Acinetobacter baumannii clinical isolates between patients with and without prior colistin treatment[J]. Ann Lab Med, 2018,38(6):545-554. [37] 韩洁, 刘宝, 万珊, 等. 2008－2014年某医院鲍曼不动杆菌的临床分布与耐药性变迁[J].贵阳医学院学报,2016,41(2):197-201. [38] 陈浩俊, 李从荣. 鲍曼不动杆菌对替加环素耐药机制的研究进展[J].中国感染与化疗杂志,2017,17(3):336-340. [39] 张驰, 杨羚, 凌保东. 鲍曼不动杆菌8种RND外排泵介导替加环素耐药表型的研究[J].中国抗生素杂志,2018,43(2):115-120. [40] 罗梦林, 刘芳, 枉前. 替加环素联合治疗鲍曼不动杆菌感染疗效的Meta分析[J].中国临床药理学杂志,2017,33(8):734-737. [41] Ramadan RA, Gebriel MG, Kadry HM, et al. Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations[J]. Infect Drug Resist, 2018,11:1261-1269. [42] 赵娜, 农凤鸣, 汤丽霞, 等. 黄连等6味中草药对耐药性鲍曼不动杆菌的抑菌作用研究[J].中国中医药科技,2018,25(5):670-671,674.
2019, Vol. 26 
